Kornimate/medical-research-clean huggingface dataset:
effect of atlas cedarwood essential oil aromatherapy on sleep quality among patients with coronary heart disease

Conditions: Sleep Quality; Coronary Heart Disease

Summary: sleep-wake disturbances were found to be a common problem among patients with chd either earlier during hospitalization or/ and after discharge although there is an evidence that sleep-wake disturbanes occur in high rate among patients with chd little was found about assessment and management of this problem. this randomized controlled study will assess sleep quality of stable chd patients who were admitted for undergoing coronary angiography electively. then it will test the hypothesis that atlas cedar wood essential oil aromatherapy have a positive effect on sleep quality of chd patients.

the primary aim is testing the effect of atlas cedar wood essential oil aromatherapy on sleep quality of patients after chd. the secondary aim is estimating the prevalence of sleep-wake disturbances (difficulty falling asleep, staying asleep, inadequate sleep duration, dissatisfaction with a sleep and excessive daytime sleepiness) among recruited chd patients. - data were collected by two phase: * phase one: sleep quality of recruited chd patients, who were admitted for undergoing coronary angiography electively, were assessed using pittsburg sleep quality index (psqi). chd participants who were reported poor sleep quality (=\>5) in psqi score will randomly allocated by toss either to intervention or control group. * phase two: 1. intervention group received an atlas cedar wood aromatherapy for five consecutive nights. 2. control group received no intervention. 3. sleep quality of both group participants re-assessed at second day and six day of recruitment, respectively, using psqi.

Eligibility criteria:
inclusion criteria: 1. stable chd patients with history of myocardial infarction, stable angina, unstable angina or acute coronary syndrome who were admitted for elective coronary angiograph (cardiac catheterization) during the study period. 2. age of participants must be between 20-64 years old. 3. participants must have an ability to understand and communicate with the researchers. exclusion criteria: included chd patient were excluded if they: 1. pregnant women or who has a plan for pregnancy as well as any patients who their care giver is pregnant 2. have a recent cardiac attack within 24-48 hours or had a history or risk of heart failure or cardiogenic shock were excluded. 3. have problems in smell sensations , history of breathing difficulties and disorders such as asthma, sleep apnea or allergies to plants and flowers parts were excluded, too. 4. have history of psychological disorders (i.e., depression) or psychiatric disorders (i.e., schizophrenia) were excluded 5. using prescribed sedatives drugs or other complementary therapy likes herbal remediates or even aromatherapy in recent one week were excluded 6. shift workers.

Keywords: sleep disturbances aromatherapy sleep quality atlas cedar wood essential oil
propofol to reduce the incidence of postanesthetic emergence agitation in pediatric patients under general anesthesia

Conditions: Pediatric ALL

Summary: this study aimed to know the effectivity of 0.5 mg/kg propofol in the end of anesthesia to reduce the incidence of postanesthetic emergence agitation in pediatric patients under general inhalation anesthesia

approval from ethical committee of faculty of medicine universitas indonesia was acquired prior conducting the study. subjects were given informed consent before enrolling the study and randomized into two groups; propofol and control. non-invasive blood pressure monitor, electrocardiogram (ecg), pulse-oxymetry, and capnograph were set on the subjects in the operation room. induction and maintenance of anesthesia will use sevoflurane. mechanical ventilation will be given to maintaining end-tidal carbon dioxide 35 to 40 mmhg. after surgery, patient will be given intravenously 15mg/kg acetaminophen, 0.05mg/kg neostigmine, and 0.02 mg/kg atropine. patient will also be given propofol 0.5 mg/kg on propofol group while no propofol will be given on control group. 30 minutes after patient was admitted to post-anesthesia care unit, patient will be evaluated for emergence agitation using aono scale and pediatric anesthesia emergence delirium scale. the incidence of emergence agitation, hypotension, and desaturation will be treated accordingly.

Eligibility criteria:
inclusion criteria: * patient undergoing non-emergency surgery with general anesthesia * patient using sevoflurane as anesthetic agent * patient aged 1 - 5 years old * american society of anesthesiologists (asa) physical status 1 - 2 * patient family signed the informed consent to be included in the study exclusion criteria: * patient that will undergo ophthalmologic and otorhinolaryngologic surgery * patient that will require post operation stay in intensive care unit * patient with psychological and neurological problem * patient with developmental delay * patient using sedative drugs * patient with allergy to propofol * patient or patient family with history of malignant hyperthermia * patient with difficulty on intubation and ventilation * patient with cardiovascular disease * patient with hemodynamic instability

Keywords: emergence agitation propofol general anesthesia
the effect of high intensity interval training on cardiovascular fitness in people with progressive multiple sclerosis.

Conditions: Multiple Sclerosis, Progressive

Summary: this is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. a control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.

this is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. a control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks. the training program will entail 6x1.5 minute intervals working at 80-95% heart rate max on a cycle ergometer. each interval will be interspersed with 1.5 minutes of working rest at a light resistance of the participant's choosing. the continuous moderate intensity exercise program will entail 20 minutes on a cycle ergometer working at 60-70% heart rate max.

Eligibility criteria:
inclusion criteria: * diagnosed with a progressive form of ms * aged 18 years or older * known to members of staff of the ms service nhs ayrshire \& arran * ability to attend douglas grant rehabilitation centre twice a week for eight weeks * edss 4-6.0 * able to cycle on ergometer exclusion criteria: * a relapse of symptoms requiring treatment within the past three months. * a respiratory condition that would be exacerbated by high intensity exercise including but not limited to: chronic obstructive pulmonary disorder, uncontrolled or poorly controlled asthma. * uncontrolled high pressure at screening (\>190/100 mmhg) * cognitive impairment affecting ability to understand instructions as noted in patient's notes. * currently engaging in another research trial for their ms or that may affect their physiological or cardiovascular outcomes * weighing more than 110 kg (weight limit of ergometer) * any pathology or medical intervention that would preclude high intensity exercise, maximal exertion testing or could attenuate the cardiovascular effect of exercise including but not limited to: unstable angina; diabetes; peripheral vascular disease or intermittent claudication; having a pace maker or medicine pump; surgical clips; having another neurological condition other than ms; and pregnancy. to be established from patient's notes and at screening session. * a serious cardiovascular event in the past year including but not limited to: transient ischaemic attack, cerebrovascular event and myocardial infarction. * taking any of the following medication: beta blockers; vasodilators; ace inhibitors; diuretics or any other medication that could cause exercise induced hypotension; hypoglycaemic insulin; metformin or other oral insulin medicine.

Keywords: progressive multiple sclerosis rehabilitation exercise
the detect hcv screening trial

Conditions: Hepatitis C

Summary: the investigators propose to compare the effectiveness of nontargeted rapid opt-out hepatitis c (hcv) screening versus targeted rapid opt-out hcv screening using recommended risk characteristics in multiple urban emergency departments (eds) across the united states (aim 1 - "screening trial").

the investigators will perform a prospective pragmatic randomized effectiveness trial that will allow the investigators to directly compare 2 hcv screening methods while minimizing threats to internal validity. patients will be screened for hcv infection using 1 of 2 interventions using a balanced patient-level random allocation scheme built into existing electronic health records (ehrs) for each ed. patients will therefore be offered hcv testing based on the result of the screening arm to which they are assigned, and in the case of the targeted arm, the results of the risk assessment evaluation performed by the intake nurse. all randomization will be completely integrated into electronic medical screening systems and workflow at each site. integration of randomization into the electronic systems will allow for real-time concealed random allocation. nurses who perform screening and all other ed staff (e.g. physicians, technicians) will understand the conceptual goals of the project but will be blinded to study hypotheses, and patients will be completely blinded to the purpose of the study. this study will be performed at multiple sites, including the eds at denver health medical center (dhmc) (denver, colorado), johns hopkins hospital (jhh) (baltimore, maryland), and the university of mississippi medical center (ummc) (jackson, mississippi).

Eligibility criteria:
inclusion criteria: * present to eds during study enrollment period * clinically stable per screening nurse or physician assessment * able to provide consent for medical care exclusion criteria: * younger than 18 years of age * are unable to consent for care (i.e., altered mentation, critical illness, or injury) * have already participated in the trial * self-identify as already living with hcv

Keywords: hepatitis c screening emergency department risk
one-year results after single-center water vapor thermal therapy for symptomatic benign prostatic hyperplasia.

Conditions: Prostatic Hyperplasia

Summary: objective: rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (bph) that uses injections of sterile water vapor directly into the prostate for tissue ablation. although rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective rezūm is for men in urinary retention. the investigators sought to determine whether rezūm is effective in the treatment of catheter-dependent urinary retention secondary to bph.

the data of participants who underwent rezūm operation with the diagnosis of bph between 2021 and 2023 were evaluated retrospectively. the investigators evaluated procedure details and evaluated pre- and post-rezūm (including international prostate symptom score (ipss), ipss quality of life (ipss-qol), prostate volumes, maximum flow (qmax), post-void residual urine volume, ieef-5, ejaculation dysfunction). the investigators examined variables at 6 and 12 months).

Eligibility criteria:
inclusion criteria: -benign prostatic hyperplasia exclusion criteria: * prostate cancer * parkinson's disease, * neurogenic bladder * overactive bladder * bladder calculus, * bladder tumor * urinary infection * alzheimer's disease
prevention of parastomal hernia with a mesh

Conditions: Parastomal Hernia

Summary: parastomal hernias are randomised to either a conventional stoma formed through the rectus anterior muscle or to the same procedure with the addition of a prophylactic mesh in a sublay position.

parastomal hernias are randomised to either a conventional stoma formed through the rectus anterior muscle or to the same procedure with the addition of a prophylactic mesh in a sublay position. randomisation is by opening closed envelopes. a low-weight,partly absorbable mesh is used. patients are followed for 5 years. clinical follow up after one month to register early complications such as wound infection or mesh infection. clinical follow up after 12 months to register parastomal herniation, fistula formation, stenosis. clinical follow up after 5 years to register parastomal herniation, fistula formation, stenosis. at this clinical follow up radiologic examination is added.

Eligibility criteria:
inclusion criteria: * clinical need of an enterostoma exclusion criteria: * patients denies inclusion in the trial.

Keywords: parastomal hernia, wound infection, stoma care.
an innovative occupational program using new technologies (kodro) life of nursing

Conditions: Home Residents

Summary: randomized controlled trial for assessing the effects resulting from an innovative occupational program using new technologies (kodro) on nursing home residents' quality of life context : improving quality of life (qol) for the nursing homes residents (nhr) is a national priority (2010 report from french anesm).

kodro stimulation program makes available stimulating activities through the use of a tactile tablet computer. these tablets are linked to an internet-based service platform the project main objective is to demonstrate by way of a randomized controlled trial the significance of the improvement of residents' qol achieved by 2 one-hour kodro sessions per week during 6 months (kodro nursing homes) when compared with the usual stimulation activity program (nursing homes "controls") (difference for the qol-ad score \> 2 points).at last, the objective of the study is also observational, i.e. to determine the quality of life of nhr at baseline, in its differents aspects.subjects \& methods analysis will be conducted to compare quantitative parameters at the beginning of the trial to verify the comparability of the two groups and of the mean average change between parameters measured at baseline, 3 months, and 6 months in both groups.

Eligibility criteria:
inclusion criteria: * nursing home residents exclusion criteria: * not able to participate in the ocupational therapy using kodro (demential end of life ...)
use of intrathecal hydromorphone in elective cesarean deliveries

Conditions: Pain

Summary: the purpose of this study is to determine if intrathecal hydromorphone will relieve pain as well as intrathecal morphine after cesarean delivery, with fewer side effects.

intrathecal morphine has long been the standard pain medication used in cesarean sections. since some patients cannot tolerate morphine, hydromorphone may be an acceptable alternative. intrathecal intrathecal hydromorphone has been shown to be effective at treating post cesarean section pain and possibly with less side effects than morphine. one side effect of morphine is respiratory depression occurring hours after the start of morphine use. respiratory depression occurs when air being taken into the lungs is less than normal, leading to a lower amount of oxygen and carbon dioxide being exchanged in the blood stream. because hydromorphone dosages are lower and it has a quicker onset of action than morphine, it is believed that the use of hydromorphone should decrease the possibility of delayed respiratory depression.

Eligibility criteria:
inclusion criteria: * scheduled for elective cesarean sections under spinal anesthesia or combined spinal anesthesia * asa status of i-iii * bmi \< 40 * able to understand and sign informed consent exclusion criteria: * severe pre-eclampsia * conversion to general anesthetic * history of chronic opioid use * allergy to morphine, or hydromorphone * hyperemesis gravidarum * emergency case * patients who have an infection at the intended site of spinal insertion

Keywords: hydromorphone morphine cesarean delivery pain management respiratory depression
role of [18f]-fdg brain pet in newly diagnosed primary cerebral lymphoma, in immunocompetent patient older than 60 years

Conditions: Primary Central Nervous System Lymphoma

Summary: patients older than 60 years account for half of cases of primary central nervous system lymphoma (pcnsl) and have a poorer outcome. no prognostic or predictive factors exist for survival after initial remission. 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose - positron emission tomography (\[18f\]fdg-pet) plays a key role in grading and therapy monitoring of systemic diffuse large b-cell type. localyze is an ancillary positron emission tomography / magnetic resonance (pet/mr) clinical study from blocage 01 (pr hoang-xuan). the aim is to evaluate the usefulness of \[18f\]fdg-pet to monitor treatment response in pcnsl older than 60 years (n=56), in complement to multiparametric magnetic resonance imaging (mri). hypothesis the investigators assume that the development of new imaging biomarker extracted from pet imaging and multiparametric mri, could improve the assessment of treatment response in pcnsl.

\[18f\]-fdg pet/mr will be performed in the department of nuclear medicine - pitié-salpêtrière hospital: * prior to initiation of chemotherapy (rituximab, methotrexate, procarbazine, vincristine and cytarabine) (pet#1), * after two chemotherapy cycles (pet#2), * at the end of the first-line chemotherapy regimens (pet#3).

Eligibility criteria:
inclusion criteria: * newly diagnosed primary cerebral lymphoma * age ≥60 years * pathology proven diagnosis or positive cytology of the cerebrospinal fluid (csf) or vitreous * karnofsky performance status ≥40 * no evidence of systemic non-hodgkin lymphomas (nhl) (body ct scan, bone marrow biopsy) * adequate haematological, renal and hepatic function * calculated creatinine clearance \> 40 ml/min exclusion criteria: * uncontrolled diabetes with fasting glycaemia \> 200 mg/dl * sensitivity to active substance in \[18f\]-fdg * calculated creatinine clearance \< 40 ml/min * no contraindication to mri (magnetic resonance imaging)
alfimeprase for thrombolysis in acute peripheral arterial occlusion

Conditions: Arterial Occlusive Diseases; Peripheral Vascular Diseases; Thrombosis

Summary: this trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. the trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).


Eligibility criteria:
* patients with acute peripheral arterial occlusion of the lower limb (onset of symptoms within 14 days) * rutherford class i or iia (minimal sensory loss, no muscle weakness, audible venous flow) * age 18 or above * able to consent * able to follow up
performance indicators of the sarc-f questionnaire in acute care

Conditions: Sarcopenia; Sensitivity; Old Age; Debility

Summary: the study applies the sluggishness, assistance in walking, rising from a chair, climb stairs, falls (sarc-f) questionnaire in older patients hospitalized in an acute care geriatric unit and aims to determine its performance indicators to screen for sarcopenia according to the revised european consensus on definition and diagnosis (ewgsop2) within this population

sarcopenia is an age-related disease associated with health adverse outcomes, i.e. higher risk of mobility limitation, falls, fractures, mortality, and lower quality of life. the european working group on sarcopenia has recently revisited one of the widely used most acknowledged definitions and launched the revised european consensus on definition and diagnosis (ewgsop2) (4). applying the ewgsop2 is a three-tier process: first, screening by the sluggishness, assistance in walking, rising from a chair, climb stairs, falls (sarc-f) questionnaire; second, diagnosis by low muscle strength, and low muscle mass; third, severity grading by low muscle function. the ewgsop2 recommends the assessment of sarcopenia in every population, both in community-dwelling and acute care older patients. however, the evidence about the performance indicators of the sarc-f questionnaire to screen for sarcopenia in acute patients admitted to an acute care unit is really limited.

Eligibility criteria:
inclusion criteria: * patients aged 65 and over * hospitalized in an acute care geriatric unit due to acute health issues or acute medical conditions * with sarc-f, hand-grip strength and dual-energy x-ray absorptiometry administered during hospital admission exclusion criteria: * sarc-f unavailable * unwilling to collaborate in the sarcopenia assessment * unwilling to sign the informed consent
survey of cannabis use in patients with chronic inflammatory arthritis

Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis

Summary: patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. they can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis. the aim of this study is to assess the percentage of patients who use cannabis to better relieve their pain or anxiety in chronic inflammatory rheumatism.

thanks to a better understanding of the pathophysiological mechanisms of inflammatory rheumatism, rheumatology has known for several decades a growth in its therapeutic arsenal (csdmards, bdmards, tdmards). rheumatism control has thus been optimized. however, patients very often keep pain, anxiety, residual fatigue, poorly controlled by our conventional therapies. patients then turn to non-drug therapies, among which the use of cannabis. endocannabinoids have an analgesic and anti-inflammatory action recognized in pre-clinical trials. however, investigators currently lack the data to authorize its use in clinical rheumatology. the aim of this study is to determine the prevalence of cannabis users in patients with rheumatoid arthritis, ankylosing spondyloarthritis or psoriatic arthritis in our unit. as a second intention, investigators will refine the consumption characteristics. investigators will also look for possible risk factors for consumption (sensitivity to pain, catastrophism, standard of living, anxiety, depression, rheumatic activity and quality of life).

Eligibility criteria:
inclusion criteria: * rheumatoid arthritis (acr 2010 criteria) * ankylosing spondylitis (new york or asas criteria) * psoriatic arthritis (caspar criteria) exclusion criteria: * patient unable to complete questionnaires or unable to express informed consent * guardianship, trusteeship, deprivation of liberties, safeguard of justice

Keywords: cannabis cannabis/therapeutic use cannabis/therapy medical marijuana chronic pain rheumatic diseases arthritis, rheumatoid spondylitis, ankylosing arthritis, psoriatic